DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
The DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index.
Abstract
Etonitazene and related 2-benzylbenzimidazoles are potent analgetics invented in the research laboratories of the Swiss pharmaceutical giant CIBA in the late 1950s. Though the unprecedented structure distinguishes this class of compounds from poppy-derived and other synthetic analgetics, a range of studies indicate that these drugs are selective μ opioid receptor agonists possessing morphine-like pharmacotoxicological properties in animals as well as humans. Several unscheduled members of this synthetically readily accessible class of opioids that are not controlled under the international and national drug control systems have recently emerged on the illicit drug market. Among them, isotonitazene has been implicated in at least 200 fatalities in Europe and North America. None of the 2-benzylbenzimidazole derivatives have been developed into medicines, but etonitazene and some of its derivatives have been used as receptor probes and in addiction behavior studies in animals. The unique structure has inspired research on such benzimidazoles and related benzimidazolones of which "brorphine" made its debut as one of the newest psychoactive substance to emerge on the illicit opioid drug market in mid-2019. This in-depth review provides a historical introduction, an overview on the chemistry, pharmacological profiles, adverse effects, addiction liability, regulatory status, and the impact on chemical neuroscience of the 2-benzylbenzimidazoles. Structurally related benzimidazoles with opioid and/or analgesic properties are also discussed briefly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug class was developed and investigated by the pharmaceutical industry in the 1950s and 1960s but never reached clinical use because the balance between their therapeutic and toxic effects was less favourable than that of morphine [3]”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [3]
In the citing paper
“While the NSO market is currently largely dominated by benzimidazole opioids (Ujváry et al., 2021)”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
In the citing paper
“Notably, brorphine appeared on recreational drug markets around the globe from 2019 onwards (Krotulski et al., 2020b; Ujváry et al., 2021; Vandeputte et al., 2022a; Verougstraete et al., 2020) and was also identified in (postmortem) toxicology samples (Krotulski et al., 2020a; Verougstraete et al., 2020; Vohra et al., 2021).”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
Citations
Cites
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Stein, C. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093100 · Cited by 480
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Properties of Opiate-Receptor Binding in Rat Brain
Pert, C. B., & Snyder, S. H. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.8.2243 · Cited by 438
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Krishna Kumar, K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., Kato, H. E., Hilger, D., Maeda, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.040 · Cited by 419
HUGHES, J., KOSTERLITZ, H. W., & LESLIE, F. M. (1975) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1975.tb07373.x · Cited by 403
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human
Morgan, M. M., & Christie, M. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01335.x · Cited by 270
Imidazole and Benzimidazole Synthesis
(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-303190-7.x5012-2 · Cited by 237
Emmerson, P. J., Liu, M. R., Woods, J. H., & Medzihradsky, F. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24051-4 · Cited by 232
Leysen, J. E., Gommeren, W., & Niemegeers, C. J. E. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90331-x · Cited by 222
The Effect of Intrinsic Efficacy on Opioid Tolerance
Duttaroy, A., & Yoburn, B. C. (1995) · Anesthesiology · doi:10.1097/00000542-199505000-00018 · Cited by 214
Therapeutic evolution of benzimidazole derivatives in the last quinquennial period
Akhtar, W., Khan, M. F., Verma, G., Shaquiquzzaman, M., Rizvi, M. A., Mehdi, S. H., Akhter, M., & Alam, M. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.010 · Cited by 214
Kawamoto, H., Ozaki, S., Itoh, Y., Miyaji, M., Arai, S., Nakashima, H., Kato, T., Ohta, H., & Iwasawa, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990517p · Cited by 204
Gates, M., & Tschudi, G. (1952) · Journal of the American Chemical Society · doi:10.1021/ja01124a538 · Cited by 183
McLean, S., Rothman, R. B., Jacobson, A. E., Rice, K. C., & Herkenham, M. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902550403 · Cited by 178
Yang, D., Fokas, D., Li, J., Yu, L., & Baldino, C. (2004) · Synthesis · doi:10.1055/s-2004-834926 · Cited by 164
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Faouzi, A., Varga, B. R., & Majumdar, S. (2020) · Molecules · doi:10.3390/molecules25184257 · Cited by 157
Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework
Krotulski, A. J., Papsun, D. M., Kacinko, S. L., & Logan, B. K. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa016 · Cited by 146
Benzimidazole: A Milestone in the Field of Medicinal Chemistry
Vasava, M. S., Bhoi, M. N., Rathwa, S. K., Jethava, D. J., Acharya, P. T., Patel, D. B., & Patel, H. D. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191122125453 · Cited by 139
Dolantin, ein neuartiges Spasmolytikum und Analgetikum
Eisleb, O., & Schaumann, O. (1939) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1120563 · Cited by 136
Wiley, J. L., Marusich, J. A., Lefever, T. W., Antonazzo, K. R., Wallgren, M. T., Cortes, R. A., Patel, P. R., Grabenauer, M., Moore, K. N., & Thomas, B. F. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225326 · Cited by 131
Differentiation of Opioid Drug Effects by Hierarchical Multi-Site Phosphorylation
Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E., Mann, A., Doll, C., Trinidad, J. C., Burlingame, A. L., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082875 · Cited by 127
Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?
Burns, G., DeRienz, R. T., Baker, D. D., Casavant, M., & Spiller, H. A. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1157722 · Cited by 126
Blanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116
Synthese basisch substituierter, analgetisch wirksamer Benzimidazol-Derivate
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161116 · Cited by 103
DARK Classics in Chemical Neuroscience: Fentanyl
Burns, S. M., Cunningham, C. W., & Mercer, S. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00174 · Cited by 103
Über eine neue Klasse von spasmolytisch und analgetisch wirkenden Verbindungen, I
Bockmühl, M., & Ehrhart, G. (1949) · Justus Liebig s Annalen der Chemie · doi:10.1002/jlac.19495610107 · Cited by 100
DARK Classics in Chemical Neuroscience: Morphine
Devereaux, A. L., Mercer, S. L., & Cunningham, C. W. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00150 · Cited by 99
Ellis, C. R., Kruhlak, N. L., Kim, M. T., Hawkins, E. G., & Stavitskaya, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197734 · Cited by 91
Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics
Grim, T. W., Acevedo‐Canabal, A., & Bohn, L. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.10.020 · Cited by 89
VITAMIN B12. VI. 5,6-DIMETHYLBENZIMIDAZOLE, A DEGRADATION PRODUCT OF VITAMIN B12
Brink, N. G., & Folkers, K. (1949) · Journal of the American Chemical Society · doi:10.1021/ja01176a532 · Cited by 89
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics
Neto, J. A., Costanzini, A., GIORGIO, R. D., Lambert, D. G., Ruzza, C., & Calò, G. (2020) · Molecules · doi:10.3390/molecules25173870 · Cited by 84
Mueller, F., Bogdal, C., Pfeiffer, B., Andrello, L., Ceschi, A., Thomas, A., & Grata, E. (2021) · Forensic Science International · doi:10.1016/j.forsciint.2021.110686 · Cited by 82
Potent, New Analgesics, Tailor‐Made for Different Purposes
Janssen, P. A. J. (1982) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1982.tb01765.x · Cited by 80
Walker, E. A., & Young, A. M. (2001) · Psychopharmacology · doi:10.1007/s002130000620 · Cited by 78
A review on synthetic approaches of benzimidazoles
Pardeshi, V. A., Chundawat, N. S., Pathan, S. I., Sukhwal, P., Chundawat, T. S., & Singh, G. P. (2020) · Synthetic Communications · doi:10.1080/00397911.2020.1841239 · Cited by 76
Rothman, R. B., Bowen, W. D., Herkenham, M. A., Jacobson, A. E., Rice, K. C., & Pert, C. B. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12341-9 · Cited by 75
Gillis, A., Sreenivasan, V., & Christie, M. J. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.119214 · Cited by 73
Ueber Reductionsprodukte der Nitracetamidverbindungen
Hobrecker, F. (1872) · Berichte der deutschen chemischen Gesellschaft · doi:10.1002/cber.18720050295 · Cited by 71
Novel benzimidazole derivatives as selective CB2 agonists
Pagé, D., Balaux, É., Boisvert, L., Liu, Z., Milburn, C., Tremblay, M., Wei, Z., Woo, S., Luo, X., Cheng, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.073 · Cited by 71
Burke, T. R., Bajwa, B. S., Jacobson, A. E., Rice, K. C., Streaty, R. A., & Klee, W. A. (1984) · Journal of Medicinal Chemistry · doi:10.1021/jm00378a008 · Cited by 71
Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430412 · Cited by 70
DARK Classics in Chemical Neuroscience: Opium, a Historical Perspective
Presley, C. C., & Lindsley, C. W. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00459 · Cited by 68
(1971) · doi:10.2172/4024824 · Cited by 68
Dolles, D., Hoffmann, M., Gunesch, S., Marinelli, O., Möller, J., Santoni, G., Chatonnet, A., Lohse, M. J., Wittmann, H.-J., Strasser, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01760 · Cited by 67
Molecular Basis of Opioid Action: From Structures to New Leads
Manglik, A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.08.028 · Cited by 66
Post-translational Modifications of Opioid Receptors
Duarte, M. L., & Devi, L. A. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.03.011 · Cited by 66
In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances
Vandeputte, M. M., Cannaert, A., & Stove, C. P. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02855-7 · Cited by 65
de la Fuente, T., Martín‐Fontecha, M., Sallander, J., Benhamú, B., Campillo, M., Medina, R. A., Pellissier, L. P., Claeysen, S., Dumuis, A., Pardo, L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901672k · Cited by 63
Über Benzimidazolderivate mit starker analgetischer Wirkung
Gross, F., & Turrian, H. (1957) · Cellular and Molecular Life Sciences · doi:10.1007/bf02161117 · Cited by 62
Danks, J. A., Tortella, F. C., Long, J. B., Bykov, V., Jacobson, A. E., Rice, K. C., Holaday, J. W., & Rothman, R. B. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90125-6 · Cited by 60
Evans-Brown, M. J., & Sedefov, R. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_160 · Cited by 59
Self-citationLadenburg, A. (1875) · Berichte der deutschen chemischen Gesellschaft · doi:10.1002/cber.187500801209 · Cited by 56
Etonitazene as a reinforcer: Oral intake of etonitazene by rhesus monkeys
Carroll, M. E., & Meisch, R. A. (1978) · Psychopharmacology · doi:10.1007/bf00426626 · Cited by 49
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430323 · Cited by 49
Inhibition and Active Sites of UDP-Glucuronosyltransferases 2B7 and 1A1.
Rios, G. R., & Tephly, T. R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1364 · Cited by 48
Zernig, G., Issaevitch, T., Broadbear, J. H., Burke, T. F., Lewis, J. W., Brine, G. A., & Woods, J. H. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02204-v · Cited by 45
First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
Verougstraete, N., Vandeputte, M. M., Lyphout, C., Cannaert, A., Hulpia, F., Van Calenbergh, S., Verstraete, A. G., & Stove, C. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa094 · Cited by 44
Wang, J., Xie, P., Xu, Y., Kettrup, A., & Schramm, K. (2004) · Atmospheric Environment · doi:10.1016/j.atmosenv.2004.07.027 · Cited by 40
Über die Umwandlung von Thebain in Oxycodeinon und dessen Derivate
Freund, M., & Speyer, E. (1916) · Journal für praktische Chemie · doi:10.1002/prac.19160940112 · Cited by 40
Butelman, E. R., France, C. P., & Woods, J. H. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10244-9 · Cited by 40
Benzimidazol‐Derivate und verwandte Heterocyclen VII. Synthese neuer 2‐Amino‐benzimidazole
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1961) · Helvetica Chimica Acta · doi:10.1002/hlca.19610440513 · Cited by 38
National Forensic Laboratory Information System
Pressley, D., Moore, K., Weimer, B., McDonald, H. S., & Ropero‐Miller, J. D. (2018) · Forensic science review · Cited by 38
Gyang, E. A., Kosterlitz, H. W., & Lees, G. M. (1964) · Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie · doi:10.1007/bf00348594 · Cited by 37
Emerging Characteristics of Isotonitazene-Involved Overdose Deaths: A Case-Control Study
Shover, C. L., Falasinnu, T. O., Freedman, R. B., & Humphreys, K. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000775 · Cited by 37
Rapid in-plate generation of benzimidazole libraries and amide formation using EEDQ
Thomas, J. B., Fall, M. J., Cooper, J., Burgess, J. P., & Carroll, F. I. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)01136-2 · Cited by 36
Bruchet, A., Prompsy, C., Filippi, G., & Souali, A. (2002) · Water Science & Technology · doi:10.2166/wst.2002.0063 · Cited by 35
Analysis of the opioid–opioid combinations according to the nociceptive stimulus in mice
Romero, A., Miranda, H. F., & Puig, M. M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.02.011 · Cited by 34
Etonitazine-induced rigidity and its antagonism by centrally acting muscle relaxants
Barnett, A., Goldstein, J. M., Fiedler, E. D., & Taber, R. I. (1975) · European Journal of Pharmacology · doi:10.1016/0014-2999(75)90197-1 · Cited by 30
�ber neue starkwirkende Analgetika und ihre klinische Erprobung
Bromig, G. (1958) · Klinische Wochenschrift · doi:10.1007/bf01486702 · Cited by 29
Drugs Affecting the Central Nervous System
Al-Zidan, R. N. (2020) · Apple Academic Press eBooks · doi:10.1201/9781003019107-7 · Cited by 28
DARK Classics in Chemical Neuroscience: Carfentanil
Ringuette, A. E., Spock, M., Lindsley, C. W., & Bender, A. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00441 · Cited by 28
Siczek, M., Zawadzki, M., Siczek, M., Chłopaś‐Konowałek, A., & Szpot, P. (2020) · Forensic Toxicology · doi:10.1007/s11419-020-00552-9 · Cited by 28
Shim, J., Coop, A., & MacKerell, A. D. (2011) · The Journal of Physical Chemistry B · doi:10.1021/jp202542g · Cited by 26
Etonitazene: An opioid selective for the mu receptor types
Moolten, M. S., Fishman, J. B., Chen, J., & Carlson, K. R. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90118-m · Cited by 26
Ligand selectivity of cloned human and rat opioid mu receptors
Rothman, R. B., Xu, H., Wang, J. B., Partilla, J. S., Kayakiri, H., Rice, K. C., & Uhl, G. R. (1995) · Synapse · doi:10.1002/syn.890210109 · Cited by 26
Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430634 · Cited by 24
Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of µ-Opioid Receptor
Kapoor, A., Provasi, D., & Filizola, M. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.119339 · Cited by 24
NOpiates: Novel Dual Action Neuronal Nitric Oxide Synthase Inhibitors with μ-Opioid Agonist Activity
Renton, P., Green, B. J., Maddaford, S. P., Rakhit, S., & Andrews, J. S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200268w · Cited by 23
Pizzonero, M., Flippen-Anderson, J. L., George, C., Bertha, C. M., & Rice, K. C. (1994) · Heterocycles · doi:10.3987/com-94-s(b)70 · Cited by 21
DARK Classics in Chemical Neuroscience: Heroin and Desomorphine
Mella, J., Romero‐Parra, J., & Recabarren‐Gajardo, G. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00262 · Cited by 20
Phosphoproteomic analysis of the mouse brain mu‐opioid (MOP) receptor
Moulédous, L., Froment, C., Burlet‐Schiltz, O., Schulz, S., & Mollereau, C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.025 · Cited by 19
Saha, P., Brishty, S. R., & RAHMAN, S. M. A. (2020) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.642 · Cited by 19
DARK Classics in Chemical Neuroscience: U-47700
Kyei‐Baffour, K., & Lindsley, C. W. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00330 · Cited by 17
XXXII. Zur Kenntniss einiger Benzimidazole
Walther, R., & von Pulawski, T. (1899) · Journal für praktische Chemie · doi:10.1002/prac.18990590117 · Cited by 16
Etonitazene. Improved synthesis
Carroll, F. I., & Coleman, M. C. (1975) · Journal of Medicinal Chemistry · doi:10.1021/jm00237a024 · Cited by 14
Differential motor effects of intraventricular infusion of morphine and etonitazene
Shizgal, P., Sklar, L. S., Brown, Z. W., & Amit, Z. (1977) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(77)90154-x · Cited by 13
Tonelli, M., Cichero, E., Mahmoud, A. M., Rabbito, A., Tasso, B., Fossa, P., & Ligresti, A. (2018) · MedChemComm · doi:10.1039/c8md00461g · Cited by 13
Similarities of the cataleptic state induced by β-endorphin and morphine
Rondeau, D. B., Turcotte, M. C., Young, L., & Hebert, D. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90350-1 · Cited by 12
CASY, A. F., & WRIGHT, J. (1966) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1966.tb07782.x · Cited by 12
Burke, T. R., Rice, K. C., Jacobson, A. E., Simonds, W. F., & Klee, W. A. (1984) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580210802 · Cited by 11
Stubbins, J. F., & Soine, T. O. (1966) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600551022 · Cited by 11
Ganellin, C. R., Loynes, J. M., Ridley, H. F., & Spickett, R. G. W. (1967) · Journal of Medicinal Chemistry · doi:10.1021/jm00317a016 · Cited by 11
Chemometrics‐assisted chromatographic fingerprinting: An illicit methamphetamine case study
Shekari, N., Vosough, M., & Heydar, K. T. (2017) · Journal of Separation Science · doi:10.1002/jssc.201601313 · Cited by 11
Baumgartner, A., Pinna, G., Hiedra, L., Bauer, F., Wolf, J., Eravci, M., Prengel, H., Brödel, O., Schmidt, G., & MEINHOLD, H. (1998) · Psychopharmacology · doi:10.1007/s002130050486 · Cited by 10
The μ-opioid receptor in the 7315c tumor cell
Tocqué, B., Jacobson, A. E., Rice, K. C., & Frey, E. A. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90742-4 · Cited by 10
Seki, T. (1967) · YAKUGAKU ZASSHI · doi:10.1248/yakushi1947.87.3_301 · Cited by 10
DARK Classics in Chemical Neuroscience: Opium, a Friend or Foe
Alam, P., Borkokoty, S., Siddiqi, M. K., Ehtram, A., Majid, N., Uddin, M., & Khan, R. H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00546 · Cited by 9
Toward a Universal μ-Agonist Template for Template-Based Alignment Modeling of Opioid Ligands
Wu, Z., & Hruby, V. J. (2019) · ACS Omega · doi:10.1021/acsomega.9b02244 · Cited by 9
Safety benefits of ‘biased’ opioids scrutinized
Servick, K. (2020) · Science · doi:10.1126/science.367.6481.966 · Cited by 9
Achat‐Mendes, C., Valdez, G. R., Platt, D. M., Rowlett, J. K., & Spealman, R. D. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1480-0 · Cited by 8
Comparison of Pharmacologic Activity in a Series of Benzimidazole Compounds
Marshall, F. N., Jones, W. R., & Weaver, L. C. (1964) · Experimental Biology and Medicine · doi:10.3181/00379727-116-29406 · Cited by 7
Studies on 2-Benzimidazolethiol Derivatives. II
Seki, T., Sasazima, M., & Watanabe, Y. (1965) · YAKUGAKU ZASSHI · doi:10.1248/yakushi1947.85.11_962 · Cited by 7
DARK Classics in Chemical Neuroscience: Krokodil
Alves, E. A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00495 · Cited by 7
Ni, Q., Xu, H., Partilla, J. S., Rice, K. C., Matecka, D., Calderon, S. N., Porreca, F., Lai, J. Y., Schmidhammer, H., Kraßnig, R., et al. (1998) · Peptides · doi:10.1016/s0196-9781(98)00046-1 · Cited by 6
Active structures in the 2-aminoethylbenzimidazoles series
Mousseron, M., Kamenka, J. M., & STENGER, A. (1968) · Journal of Medicinal Chemistry · doi:10.1021/jm00310a045 · Cited by 6
Yücel, N. T., Özkay, Ü. D., Can, N. Ö., & Can, Ö. D. (2018) · Letters in Drug Design & Discovery · doi:10.2174/1570180815666181004103112 · Cited by 6
International Narcotics Control Board (2019) · Narcotic drugs. Estimated world requirements for... Statistics for ... · doi:10.18356/ba5179d3-en-fr-es · Cited by 6
The synthesis of some 1‐(β‐diethylaminoethyl)‐2‐(p‐ethoxybenzyl)‐5‐substituted benzimidazoles
Carroll, F. I., Handy, R. W., Kepler, J. A., & Gratz, J. A. (1967) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570040217 · Cited by 5
X-ray Analysis and the Structure of Vitamin B12
Hodgkin, D. C. (1958) · Springer eBooks · doi:10.1007/978-3-7091-7162-2_4 · Cited by 5
Effects of etonitazene upon respiratory neurons
Carregal, E. J. A., & Williams, B. (1967) · Cellular and Molecular Life Sciences · doi:10.1007/bf02142268 · Cited by 4
Synthesis and antinociceptive activities of some novel benzimidazole-piperidine derivatives
Özkay, Ü. D., Can, Ö. D., Yücel, N. T., & Kaya, B. (2017) · TURKISH JOURNAL OF CHEMISTRY · doi:10.3906/kim-1612-76 · Cited by 4
Opioid Receptors: Facts and Speculations
CASY, A. F., & Parfitt, R. T. (1986) · Springer eBooks · doi:10.1007/978-1-4899-0585-7_13 · Cited by 3
Seki, T., & Watanabe, Y. (1969) · YAKUGAKU ZASSHI · doi:10.1248/yakushi1947.89.5_617 · Cited by 2
SYNTHESIS OF 2-(1-(4-CHLOROPHENYL) ETHYL)-1-(2- (DIETHYLAMINO) ETHYL)-1H-BENZO[D]IMIDAZOL-5- AMINE
Marupati, S., Eppakayala, L., & Gade, D. (2018) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2018.1144087 · Cited by 2
Research works printed but not linked: 36
- Gulland J. M., 1925, Mem. Proc. Manchester Lit. Philos. Soc., 69, 79
- European Monitoring Centre for Drugs and Drug Addiction, 2020, European Drug Report 2020: Trends and Developments
- United Nations Office on Drugs and Crime, 2021, World Drug Report 2020
- United Nations Office on Drugs and Crime. growing complexity of the opioid crisis. Global SMART Update Vol. 24, UNODC, Vienna, 2020. https://www.unodc.org/documents/scientific/Global_SMART-2020-Vol_24_web.pdf (accessed Feb 24, 2021).
- Grimmett M. R., 2002, Hetarenes and Related Ring Systems. Five-Membered Hetarenes with Two Nitrogen or Phosphorus Atoms, Science of Synthesis, 12, 529
- StarDrop , version 6.6 software, Optibrium Ltd., Cambridge, U.K.
- Sparatore F., 1968, Farmaco, Ed. Sci., 23, 344
- Bucha M., 2018, Indian J. Heterocycl. Chem., 28, 321
- European Monitoring Centre for Drugs and Drug Addiction, 2020, Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No. 1920/2006 (as amended)
- Gonthier, V. Une toute nouvelle drogue inquiete les autorites. Le Journal du Quebec. 1 Février, 2020. https://journaldequebec.com/2020/02/01/une-toute-nouvelle-drogue-inquiete-les-autorites (accessed Feb 24, 2021).
- Sorokin V. I., 1999, J. Clandestine Lab. Invest. Chem. Assoc., 9, 20
- Brittain R. T., 1973, Br. J. Pharmacol., 49, 158P
- Jacobson A. E., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 490
- Aceto M. D., 1994, Problems of Drug Dependence, 1993, NIDA Research Monograph Series 140, 103
- Aceto M. D., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 513
- Eddy N. B., 1959, Chem. Ind., 47, 1462
- Fraser H. F., 1960, Minutes of the Twenty-First Meeting, 11–12 January, 1960, Committee on Drug Addiction and Narcotics, 35
- 1961, World Health Organization Technical Report Series No. 211, 1
- Butelman E. R., 1993, J. Pharmacol. Exp. Ther., 264, 145
- Emmerson P. J., 1994, J. Pharmacol. Exp. Ther., 271, 1630
- Toll L., 1998, NIDA Research Monograph Series 178, 440
- Rothman R. B., 1985, Mol. Pharmacol., 27, 399
- Lecolier S., 1967, Chim. Ther., 2, 16
- Lénárd K., 1962, Acta Chim. Acad. Sci. Hung., 34, 439
- Janssen P. A. J., 1971, Arzneim.-Forsch., 21, 862
- Li Q., 1984, Acta Pharm. Sin., 19, 124
- Department of Justice., 2021, Fed. Regist., 86, 11862
- Holliday E. R., 1949, J. Pharm. Pharmacol., 1, 734
- Ramsh S. M., 2011, Stud. Hist. Biol., 3, 36
- Feitelson B. N., 1958, J. Chem. Soc., 2426
- Brandenberger H., 1974, Dtsch. Lebensmitt. Rundsch., 70, 31
- Anonymous., 1987, BKA - Wöchentlicher Lagebericht, 87, 9
- Sorokin V. I., 1999, Microgram, 32, 239
- Anonymous., 2003, Microgram Bull., 36, 275
- deStevens G., 1965, Analgetics, 405
- Archer S., 1965, Progr. Drug Res., 8, 261
Cited by
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Treatment of overdose in the synthetic opioid era
Skolnick, P. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108019 · Cited by 127
Krotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91
Montanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89
Nitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86
Metadata
- Authors
- Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R.
- Affiliations
- iKem BT, H-1033 Budapest, Hungary
- European Monitoring Centre for Drugs and Drug Addiction (PT)
- European Monitoring Centre for Drugs and Drug Addiction, 1249-289 Lisbon, Portugal
- Corresponding author
- Ujváry, István
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-24
- Volume
- 12
- Issue
- 7
- Pages
- 1072-1092
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3137216449
- Cited by
- 141
- References
- 121
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 27 · 2023: 20 · 2022: 21 · 2021: 8
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Monitoring Centre for Drugs and Drug Addiction (CT.20.SAS.0017.1.0)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- etonitazene, isotonitazene, mu-opioid receptor agonists, synthetic opioids, benzimidazolone, analgesics, drug regulation, addiction liability, pharmacotoxicology, Ciba, drug development history
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Europe, Humans, Morphine, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.